

US00RE46912E

(19) **United States**
 (12) **Reissued Patent**
Kang et al.

(10) **Patent Number: US RE46,912 E**
 (45) **Date of Reissued Patent: Jun. 26, 2018**

(54) **LACTIC ACID BACTERIA ISOLATED FROM MOTHER'S MILK WITH PROBIOTIC ACTIVITY AND INHIBITORY ACTIVITY AGAINST BODY WEIGHT AUGMENTATION**

7,115,291 B1 * 10/2006 Kuma A23C 9/1307
 426/43
 7,807,440 B2 * 10/2010 Molin et al. A23C 9/123
 435/252.1
 2004/0115179 A1 6/2004 Liu et al.

(71) Applicant: **Bioneer Corporation**, Daejeon (KR)
 (72) Inventors: **Ji Hee Kang**, Daejeon (KR); **Byeung I. You**, Daejeon (KR); **Sung I. Yun**, Daejeon (KR); **Han O. Park**, Daejeon (KR)

FOREIGN PATENT DOCUMENTS

JP 2005-080636 A 3/2005
 WO 2004/003235 A3 1/2004

(73) Assignee: **BIONEER CORPORATION**, Daejeon (KR)

OTHER PUBLICATIONS

(21) Appl. No.: **14/537,565**
 (22) Filed: **Nov. 10, 2014**

Kirjavainen et al., FEMS Immunol. and Med. Micro., 26:131-35, 1999.*
 Usman et al., J. of Dairy Res., 2001:617-624.*
 StrainInfobeta F. Gasser AM 63.*
 Accessions AF243173, AF243144, AF243156, 519171.*
 Jackson et al., 2002, J. of Microbiol. Methods 51:313-321.*
 Mosca et al., Human milk: composition and health benefits, La Pediatria Medica e Chirurgica, v.39:155, pp. 47-52, 2017.*
 Pavlova et al 2002, J. Appl. Microbiol. 92 (3), 451-459.*
 Supplementary European Search Report issued in EP Appln. No. 07 74 6512, dated Aug. 17, 2010, 2 pages.
 A. C. Majhenic, et al.: "DNA analysis of the genes encoding acidocin LF221 A and acidocin LF221 B, two bacteriocins produced by *Lactobacillus gasseri* LF221," Appl. Microbiol. Biotechnol., vol. 63, Sep. 18, 2003, pp. 705-714.
 NCBI GenBank Accession No. AY297947: "*Lactobacillus gasseri* putative complement factor, acidocin LF221B, and putative immunity protein genes, complete cds; and unknown genes," Nov. 4, 2005, 2 pages.
 Y. Kawai et al.: "Primary Amino Acid and DNA Sequences of Gassericin T, a Lactacin F-Family Bacteriocin Produced by *Lactobacillus gasseri* SBT2055," in Biosci. biotechnol. Biochem, vol. 64(10), Jun. 6, 2000, pp. 2201-2208.
 NCBI GenBank Accession No. AB029612: "*Lactobacillus gasseri* gassericin T gene region (ORF1, ORF2, ORF3, gatA, gatX, ORF6), complete cds," Oct. 27, 2000, 3 pages.
 Majhenic, A.G. et al., DNA analysis of the genes encoding acidocin LF221 A and acidocin LF221 B, two bacteriocins produced by *Lactobacillus gasseri* LF221, Appl. Microbiol. Biotechnol., vol. 63, pp. 705-714. (2004).

Related U.S. Patent Documents

Reissue of:
 (64) Patent No.: **8,309,076**
 Issued: **Nov. 13, 2012**
 Appl. No.: **12/376,368**
 PCT Filed: **May 14, 2007**
 PCT No.: **PCT/KR2007/002363**
 § 371 (c)(1),
 (2) Date: **Mar. 17, 2010**
 PCT Pub. No.: **WO2008/016214**
 PCT Pub. Date: **Feb. 7, 2008**

(30) Foreign Application Priority Data

Aug. 4, 2006 (KR) 10-2006-0073722

(51) **Int. Cl.**
A61K 35/74 (2015.01)
C12N 1/20 (2006.01)
C12R 1/225 (2006.01)
A23L 33/18 (2016.01)
A23L 33/135 (2016.01)
A23C 9/123 (2006.01)
C07K 14/335 (2006.01)
A61K 38/00 (2006.01)

(52) **U.S. Cl.**
 CPC **C12R 1/225** (2013.01); **A23C 9/1234** (2013.01); **A23L 33/135** (2016.08); **A23L 33/18** (2016.08); **C07K 14/335** (2013.01); **C12N 1/20** (2013.01); **A23Y 2220/37** (2013.01); **A61K 38/00** (2013.01)

(58) **Field of Classification Search**
 CPC A23C 9/1234; C07K 14/335; C12N 1/20; C12R 1/225; A23L 33/135; A23L 33/18; A23Y 2220/37; A61K 8/00
 See application file for complete search history.

(56) References Cited

U.S. PATENT DOCUMENTS

6,004,551 A * 12/1999 Reid A61K 9/0034
 424/430
 6,808,703 B2 10/2004 Park et al.
 6,942,857 B2 9/2005 Song et al.
 7,001,756 B1 2/2006 Hsu et al.

* cited by examiner

Primary Examiner — Sharon Turner

(74) Attorney, Agent, or Firm — Sughrue Mion, PLLC

(57) ABSTRACT

The present invention relates to a lactic acid bacterium isolated from human mother's milk, more precisely a *Lactobacillus gasseri* BNR17 strain that is isolated from Korean mother's milk and has excellent probiotic activity including acid resistance, bile acid resistance and antimicrobial activity and weight gaining inhibitory effect as well. Again, the *Lactobacillus gasseri* BNR17 of the present invention has excellent acid resistance, bile acid resistance, enteric absorption activity and antimicrobial activity against pathogenic microorganisms, in addition to the weight gaining inhibitory effect by synthesizing indigestible polysaccharides from monosaccharides included in food taken and releasing the synthesized polysaccharides out of the body. Therefore, the strain of the invention, owing to such beneficiary effects, can be effectively used not only for the production of fermented milk, other fermented food products and animal feeds but also for the production of live cell products and food additives for preventing weight gaining.

23 Claims, 4 Drawing Sheets

[Fig. 1]

BNR17 GCTGACTCCTATAAAGGTTATCCCACCGGCTTTGGGTGTTACAGACTCTCATGGTGTGAC 88
AF243156 GCTGACTCCTATAAAGGTTATCCCACCGGCTTTGGGTGTTACAGACTCTCATGGTGTGAC 120

BNR17 GGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCGTGCTGATCCGCGATTACTA 148
AF243156 GGGCGGTGTGTACAAGGCCCGGGAACGTATTCACCGCGGCGTGCTGATCCGCGATTACTA 180

BNR17 GCGATTCCAGCTTCGTGTAGGCGAGTTGCAGCCTACAGTCCGAACTGAGAACGGCTTTCA 208
AF243156 GCGATTCCAGCTTCGTGTAGGCGAGTTGCAGCCTACAGTCCGAACTGAGAACGGCTTTCA 240

BNR17 NAGATCCGCTTGCCCTTCGCAGGTTGCTTCTCGTTGTACCGTCCATTGTAGCACGTGTGT 268
AF243156 GAGATCCGCTTGCCCTTCGCAGGTTGCTTCTCGTTGTACCGTCCATTGTAGCACGTGTGT 300

BNR17 AGCCCAGGTCATAAGGGGCATGATGACTTGACGTCATCCCCACCTTCCTCCGGTTTGTCA 328
AF243156 AGCCCAGGTCATAAGGGGCATGATGACTTGACGTCATCCCCACCTTCCTCCGGTTTGTCA 360

BNR17 CCGGCAGTCTCATTAGAGTGCCCAACTTAATGATGGCAACTAATGACAAGGGTTGCGCTC 388
AF243156 CCGGCAGTCTCATTAGAGTGCCCAACTTAATGATGGCAACTAATGACAAGGGTTGCGCTC 420

BNR17 GTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCATGCACCACCTGT 448
AF243156 GTTGCGGGACTTAACCCAACATCTCACGACACGAGCTGACGACAGCCATGCACCACCTGT 480

BNR17 CTCAGCGTCCCCGAAGGGAACCTCCTAATCTCTTAGGTTTGCAGTGGATGTCAAGACCTGG 508
AF243156 CTCAGCGTCCCCGAAGGGAACCTCCTAATCTCTTAGGTTTGCAGTGGATGTCAAGACCTGG 540

BNR17 TAAGGTTCTTCGCGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCG 568
AF243156 TAAGGTTCTTCGCGTTGCTTCGAATTAAACCACATGCTCCACCGCTTGTGCGGGCCCCCG 600

BNR17 TCAATTCCTTTGAGTTTCAACCTTGCGGTCGTA TCCCAGGCGGAGTGCTTAATGCGTT 628
AF243156 TCAATTCCTTTGAGTTTCAACCTTGCGGTCGTA TCCCAGGCGGAGTGCTTAATGCGTT 660


BNR17 AGCTGCAGCACTGAGAGGCGGAAACCTCCCAACACTTAGCACTCATCGTTTACGGCATGG 688
AF243156 AGCTGCAGCACTGAGAGGCGGAAACCTCCCAACACTTAGCACTCATCGTTTACGGCATGG 720

BNR17 ACTACCAGGGTATCTAATCCTGTTGCTACCCATGCTTTGAGCCTCAGCGTCAGTTGCA 748
AF243156 ACTACCAGGGTATCTAATCCTGTTGCTACCCATGCTTTGAGCCTCAGCGTCAGTTGCA 780


BNR17 GACCAGAGAGCCGCTTCGCCACTGGTGTCTTCCATATATCTACGCATTCACCGCTAC 808
AF243156 GACCAGAGAGCCGCTTCGCCACTGGTGTCTTCCATATATCTACGCATTCACCGCTAC 840

BNR17 ACATGGAGTTCCACTCTCCTCTTCTGCACTCAAGTTCAACAGTTTCTGATGCAATTCTCC 868
AF243156 ACATGGAGTTCCACTCTCCTCTTCTGCACTCAAGTTCAACAGTTTCTGATGCAATTCTCC 900


[Fig. 2]




[Fig. 3]




[Fig. 4]




[Fig. 5]



[Fig. 6]



[Fig. 7]



1

**LACTIC ACID BACTERIA ISOLATED FROM
MOTHER'S MILK WITH PROBIOTIC
ACTIVITY AND INHIBITORY ACTIVITY
AGAINST BODY WEIGHT AUGMENTATION**

Matter enclosed in heavy brackets [] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue; a claim printed with strikethrough indicates that the claim was canceled, disclaimed, or held invalid by a prior post-patent action or proceeding.

**CROSS REFERENCE TO RELATED
APPLICATIONS**

This application is a *reissue application of U.S. Pat. No. 8,309,076, issued on Nov. 13, 2012, which issued from the 35 U.S.C. § 371 National Phase Entry Application from PCT/KR2007/002363, filed May 14, 2007, and designating the United States, which claims priority under 35 U.S.C. § 119 to Korean Patent Application No. 10-2006-0073722 filed Aug. 4, 2006, which is incorporated herein in its entirety.*

SEQUENCE LISTING

The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to a probiotic lactic acid bacterium, more specifically a novel lactic acid bacterium belonging to *Lactobacillus* sp. isolated from human mother's milk and having excellent probiotic activity such as acid resistance, bile acid resistance and antimicrobial activity and inhibitory activity against body weight augmentation.

DESCRIPTION OF THE RELATED ART

A lactic acid bacterium shares a long history with human, which is the microorganism that is very profitable for human health and thus in the increasing demand. According to the recent progress of the lactic acid bacterium studies, its applicability has been broadened from general foods to health food and medicines. A lactic acid bacterium is exemplified by *Streptococcus* sp., *Pediococcus* sp., *Leuconostoc* sp., *Lactobacillus* sp., *Sporolactobacillus* sp. and *Bifidobacterium* sp. microorganisms.

Lactic acid bacteria inhabit in the animal's intestines where they decompose nutrients and cellulose that the host animal has taken and then use them as an energy source to produce lactic acid and antibiotics in order to inhibit the growth of pathogenic bacteria in the intestine to keep the intestine healthy. The lactic acid bacteria have also been used for stimulation of animal growth, improvement of feed utilization, enhancement of resistance against disease, inhibition of the growth of pathogenic bacteria, reduction of mortality, inhibition of the generation of toxic substances and production of various vitamins.

However, to be effective in the intestine, the incoming lactic acid bacteria from outside have to arrive to the intestines safe and be attached onto the mucous membrane to be functioning. To do so, lactic acid bacteria have to be the one that is able to adhere directly onto the mucous membrane of the intestine, has to be less destroyed by

2

gastric acid when it is orally administered, has to have strong resistance against bile acid and has to have strong antimicrobial activity against pathogens.

When lactic acid bacteria are used for food or medicine for human health, they are supposed to be isolated from human for better effect. In particular, the lactic acid bacteria isolated from mother's milk have been acknowledged to be more effective and safer. However, the human originated lactic acid bacteria have been mostly isolated from adult's feces or breast-fed infant's feces. The lactic acid bacteria isolated from mother's milk are mostly *Lactobacillus reuteri* and other lactic acid bacteria have hardly been reported.

Meanwhile, obesity is a chronic disease whose cause has not been exactly disclosed but whose development is believed to be attributed to the co-work of several different factors. Obesity might cause hypertension, diabetes, cardiovascular disease, gallstone, osteoarthritis, sleep apnea syndrome, breathing disorder, prostatic cancer, breast cancer, colon cancer, etc. The conventional methods hired for the prevention and treatment of obesity are largely diet-exercise therapy, surgical operation, drug therapy, etc. The diet-exercise therapy is to encourage taking low-calorie-low fat food and physical exercise to consume oxygen. This method requires patience since it has to be carried out repeatedly and persistently and that is why this method seems to be ineffective for the general public. The surgical operation is to eliminate body fat by surgery. This method has an advantage of obtaining the desired results in a short time but at the same time has disadvantages of painful surgery, doubt of the continuance of the effect and high costs. The drug therapy needs careful attention because it carries many side effects.

Recently, studies on polysaccharides produced by lactic acid bacteria have been actively undergoing. The mechanism that lactic acid bacteria produce extracellular polysaccharides is known to be very complicated. There are huge differences in productivity and the structure of the polysaccharides according to the kinds of lactic acid bacteria. Polysaccharides produced by lactic acid bacteria have been reported to have anticancer activity and immune enhancing activity (Kitazawa, H. *Int. J. Food Microbiol.*, 1998. 40. 169-175, Hosono, A. *Biosci. Biotechnol. Biochem.*, 1997. 61. 312-316, Chabot, S. *Lait*. 2001. 81. 683-697). It is also expected to be very safe to take the polysaccharides produced by lactic acid bacteria because lactic acid bacteria themselves are classified as GRAS (Generally Recognized As Safe).

SUMMARY OF THE INVENTION

The present invention relates to a lactic acid bacterium isolated from human mother's milk, and it is an object of the present invention to provide a lactic acid bacterium that has strong resistance against acid, pH and bile acid and strong adherence to intestines so as to convert low-molecular carbohydrates decomposed by a digestive enzyme into high-molecular polysaccharides and to excrete the polysaccharides instead of letting it be absorbed in the body.

**DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENTS**

To achieve the above object, the present invention provides a *Lactobacillus gasseri* BNR17 strain, the lactic acid bacterium isolated from human mother's milk.

The lactic acid bacteria strain of the present invention has following characteristics.

3

① Morphology—morphology after culture at 37° C. for 24 hours on the Lactobacilli MRS agar plate medium:

i. Shape, size and color of colony: round, 0.5 mm×2 mm, milk-white color, smooth surface.

ii. Gram staining: positive.

iii. Type: rod type (Bacillus).

iv. Sporulation: no.

v. Mobility: no.

② Physiological properties

i. Growth temperature: 25~45° C.

ii. Growth pH: pH 4.0~10.0

iii. Optimum growth temperature: 37~40° C.

iv. Optimum growth pH: pH 6.0~8.0

③ Influence of oxygen: facultative anaerobic.

④ Sugar availability:

Glycerol -, Ribose -, Adonitol -, Galactose +, D-Glucose +, D-Fructose +, D-Mannose +, Mannitol -, Sorbitol -, N-Acetylglucoside +, Esculin +, Salicin +, Cellobiose +, Maltose +, Lactose +, Melibiose -, Saccharose +, Trehalose +, Inulin -, Melezitose -, Raffinose -, Starch -, β -Gentiobiose -, D-Turanose +, D-Tagatose +

⑤ Acid resistance: survived at pH 2.0.

⑥ Bile acid resistance: survived at 0.3% of bile acid.

⑦ Adherence to intestines: adhered to Caco-2 cells, the human intestinal epithelial cells.

⑧ Antibiotic resistance: resistant to Gentamycin, Kanamycin, Streptomycin, Bacitracin, Neomycin, Nalidixic acid, Ciprofloxacin, Polymyxin B and Trimethoprim.

sensitive to Erythromycin, Penicillin, Tetracycline, Ampicillin, Chloramphenicol, Vancomycin and Cefoxitin, Rifampin.

⑨ Antimicrobial activity to pathogenic bacteria: antimicrobial activity to *E. coli*, *S. aureus*, *S. typhimurium*, *B. cereus*, *L. monocytogenes*, and *P. mirabilis*.

⑩ Presence of antimicrobial peptide: The gene corresponding to gasserin T of bacteriocin, one of antimicrobial peptide components of lactic acid bacteria, is detected by PCR.

⑪ Polysaccharide generation: The lactic acid bacterium of the present invention produces approximately 520 mg/L of polysaccharides after 24 hours of culture on the MRS medium supplemented with 2% glucose. The polysaccharides were composed mainly of glucose, mannose, galactose, fucose, arabinose and D-glucosamine. The polysaccharides produced by the lactic acid bacterium of the present invention are not decomposed by digestive enzymes such as α -amylase and pancreatine.

Koreans have different diet habit with westerners. So, it is clear and natural that the lactic acid bacterium isolated from Koreans have different dietary habits with westerners. So, it is clear and natural that the lactic acid bacterium isolated from Korean best fits to Korean. The lactic acid bacterium isolated from Korean mother's milk fulfills every required fundamental condition for probiotic lactic acid bacterium, resulting in the best health enhancing effect for Korean. The present inventors named such lactic acid bacterium having the above characteristics as "Lactobacillus gasseri BNR17" and deposited at Korean Collection for Type Cultures (KCTC) of Korea Research Institute of Biotechnology and Bioscience (KRIBB), located at #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea, on Jan. 23, 2006 (Accession No: KCTC 10902BP).

The present invention also provides a composition containing an effective dose of the lactic acid bacterium. The composition of the present invention can be provided in the forms of food, food additives, animal feeds and animal feed additives.

4

The novel lactic acid bacterium provided by the invention, *Lactobacillus gasseri* BNR17 (Accession No: KCTC 10902BP) has excellent acid resistance, bile acid resistance and antimicrobial activity, making it an excellent candidate as a seed for the production of various fermented milk products and other fermented foods. The fermented milk products herein can be exemplified by yoghurt, calpis, cheese and butter, and the other fermented foods herein can be exemplified by tofu, soy bean paste, Chungkukjang, jelly and Kimchi, but not always limited thereto. The fermented milk products and fermented foods can be easily produced by the conventional method only with substituting the strain with the lactic acid bacterium of the invention.

According to a preferred embodiment of the present invention, approximately 7.7% weight gaining inhibitory effect was observed in the experimental group rats administered with *Lactobacillus gasseri* BNR17, compared with the control group rats administered with PBS (phosphate-buffered saline)(see Table 6). In addition to the weight gaining inhibitory effect, diet efficiency in the experimental group was also reduced significantly, compared with the control group. Polysaccharides included in feces of both experimental and control groups were examined. As a result, the polysaccharide content in feces of experimental group was higher than that of control group (see FIG. 6). These results indicate that the indigestible polysaccharide producing capacity of *Lactobacillus gasseri* BNR17 plays a certain role in weight regulation. In the meantime, no superficial side effects have been detected in the experimental group rats taking *Lactobacillus gasseri* BNR17 and the weight of each organ was not much different from that of control group (see Table 7 and Table 8). Microorganism transition, one of major concerns when human takes a microorganism, was not observed, suggesting that the lactic acid bacterium of the present invention is very safe for human to take (see FIG. 7).

The lactic acid bacterium food products of the present invention can be produced as an edible form of composition either containing *Lactobacillus gasseri* BNR17 alone or with any acceptable carrier. The lactic acid bacterium of the invention can be added to the food that does not contain any probiotic bacteria or the food that already contains several kinds of probiotic bacteria. The microorganism that can be co-used with the lactic acid bacterium of the invention to produce the lactic acid bacterium food has to be appropriate for intake by human or animals and have probiotic activity such as inhibiting pathogenic bacteria or improving the balance of microorganisms in the mammal's intestines, but not always limited thereto. The probiotic microorganism is exemplified by yeasts such as *Saccharomyces*, *Candida*, *Pichia* and *Torulopsis*; fungi such as *Aspergillus*, *Rhizopus*, *Mucor* and *Penicillium*; and bacteria belonging to *Lactobacillus*, *Bifidobacterium*, *Leuconostoc*, *Lactococcus*, *Bacillus*, *Streptococcus*, *Propionibacterium*, *Enterococcus* and *Pediococcus*. Preferably, the probiotic microorganism can be selected from the group consisting of *Saccharomyces cerevisiae*, *Bacillus coagulans*, *Bacillus licheniformis*, *Bacillus subtilis*, *Bifidobacterium bifidum*, *Bifidobacterium infantis*, *Bifidobacterium longum*, *Enterococcus faecium*, *Enterococcus faecalis*, *Lactobacillus acidophilus*, *Lactobacillus alimentarius*, *Lactobacillus casei*, *Lactobacillus curvatus*, *Lactobacillus delbruckii*, *Lactobacillus johnsonii*, *Lactobacillus farciminus*, *Lactobacillus gasseri*, *Lactobacillus helveticus*, *Lactobacillus rhamnosus*, *Lactobacillus reuteri*, *Lactobacillus sakei*, *Lactococcus lactis* and *Pediococcus acidilactici*. It is more preferred to add a probiotic microorganism mixture having excellent probiotic activity and immune enhancing activity as well as anticancer activity to the lactic acid

bacterium food of the invention, resulting in greater effect. A carrier acceptable for the lactic acid bacterium food of the invention is exemplified by a diluent, a high-fiber additive, an encapsulant and a lipid, which have been well informed to those skilled in the art. The lactic acid bacterium of the invention, *Lactobacillus gasseri* BNR17, can be formulated as capsules, culture suspension or dried powder.

In addition, the composition containing the lactic acid bacterium of the invention can be prepared as animal feeds or animal feed additives.

The animal feed additive of the invention can be prepared in dried or liquid form and can contain other non-pathogenic microorganisms in addition to the *Lactobacillus gasseri* BNR17. The addable microorganism can be selected from the group consisting of *Bacillus subtilis* producing protease, lipase and sugar converting enzyme; *Lactobacillus* strain having organic decomposition activity and maintaining physical activities under anaerobic condition; filamentous fungi such as *Aspergillus oryzae* (Slyter, L. L. *J. Animal Sci.* 1976, 43, 910-926) contributing to the increase of milk and weight of cattle and feed digestibility as well; and yeast such as *Saccharomyces cerevisiae* (Johnson, D. E et al. *J. Anim. Sci.*, 1983, 56, 735-739; Williams, P. E. V. et al, 1990, 211).

The animal feed additive of the present invention can additionally include one or more enzyme products in addition to the *Lactobacillus gasseri* BNR17. The addable enzyme product can be in dried or liquid form, which is selected from the group consisting of lipase, phytase decomposing phytic acid into phosphate and inositol phosphate, amylase hydrolyzing α -1,4-glycoside bond included in starch and glycogen, phosphatase hydrolyzing organic phosphoric acid ester, carboxymethylcellulase decomposing cellulose, xylase decomposing xylose, maltase hydrolyzing maltose into two glucoses and invertase hydrolyzing saccharose into glucose-fructose.

When the lactic acid bacterium of the invention is added to the animal feed as an additive, the proper feed raw material is selected from the group consisting of crops, soybean protein, peanut, green pea, sugar beet, pulp, crop byproduct, animal intestine powder and fish powder. At this time, these materials can be used as they are or after being processed. To process the animal feed, for example, raw material for feed is compressed by pressure to be discharged, but not always limited thereto. In the case of using a protein as a raw material, extrusion is preferred. Particularly, extrusion is to denature a protein by heat-treatment, resulting in the destruction of anti-enzyme factors. More specifically, in the case of using a soybean protein, extrusion improves the digestibility of the protein, inactivates anti-nutrition factors such as trypsin inhibitor, one of protease inhibitors, and increases digestibility by a protease, resulting in the increase of nutritional value of the protein.

The present invention further provides a pharmaceutical composition for the prevention and treatment of obesity which contains the effective dose of *Lactobacillus gasseri* BNR17 (Accession No: KCTC 10902BP).

The *Lactobacillus gasseri* BNR17 of the invention is generally administered as a tablet or a capsule prepared by mixing the lactic acid bacterium with a pharmaceutically acceptable carrier, an excipient or another effective supplementary component.

The acceptable carrier, excipient or diluent for the pharmaceutical composition of the invention is exemplified by lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, tragacanth gum, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl-

hydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil. The microorganism composition of the invention can additionally include lubricants, wetting agents, emulsifying agents, suspension agents, preserving agents, sweetening agents or flavors. The composition of the invention can be prepared in the form of enteric coated preparation in order for the composition to pass through the stomach and reach the small intestine safely and to release microorganism, the active ingredient, therein fast and easy, according to the conventional method well known to those skilled in the art.

The microorganism composition of the present invention can also be prepared in the form of a capsule, according to the conventional capsule production method. For example, a standard carrier is used for the preparation of a pellet containing the freezing-dried microorganism of the invention, which fills soft gelatin capsules. Another example is that the microorganism of the invention is mixed with a pharmaceutically acceptable carrier, for example soluble gum, cellulose, silicate or oil, to prepare suspension or dispersing solution, which fills soft gelatin capsules.

The pharmaceutical composition of the present invention can be provided as a unit drug form for oral administration as an enteric coated preparation. "Enteric coating" herein indicates that a drug is not decomposed by gastric acid and maintained as being coated but is decomposed in the small intestine to release active ingredients therein, which includes every kind of pharmaceutically acceptable coatings. "Enteric coating" of the invention is maintained at least two hours in the artificial gastric juice such as HCl solution (pH 1) at 36-38° C. but the coating is preferably decomposed within 30 minutes in the artificial intestinal juice such as KH_2PO_4 buffer solution (pH 6.8).

Enteric coating of the invention is performed, in which one core is coated by 16-30 mg, preferably 16-20 mg or less than mg of the composition. The preferable thickness of the coating is 5-100 μm and more preferably 20-80 μm for the best results. Materials for the enteric coating can be selected among the well-informed high molecular substances. Those high molecular substances are described in numbers of references (L. Lachman, et al., *The Theory and Practice of Industrial Pharmacy*, 3rd edition, 1986, pp. 365-373; H. Sucker, et al., *Pharmazeutische Technologie*, Thieme, 1991, pp. 355-359; Hagers *Handbuch der pharmazeutischen Praxis*, 4th edition, Vol. 7, pp. 739-742, and 766-778, (SpringerVerlag, 1971); and Remington's *Pharmaceutical Sciences*, 13th edition, pp. 1689-1691 (Mack Publ., Co., 1970)), which can be exemplified by cellulose ester derivatives, cellulose ether, methylacrylate copolymer of acrylic resin and copolymer of maleic acid and phthalic acid derivatives.

The enteric coating of the invention can be performed by the conventional method which is spraying the coating solution onto a core. The acceptable solvent for the enteric coating is selected from the group consisting of alcohol such as ethanol, ketone such as acetone, halogenized hydrocarbon such as CH_2Cl_2 and a mixture thereof. A softener such as di-n-butylphthalate or triacetone can be added to the coating solution at the ratio of 1:0.05-0.3 (coating material:softener). It is preferred to spray serially and the amount of spray is determined by considering the coating conditions. Spraying pressure can be regulated and generally 1-1.5 bar is considered to give best results.

The "pharmaceutically effective dosage" of the invention indicates the minimum amount of the microorganism of the invention that is able to reduce low-sugar carbohydrates to be absorbed into the intestines of mammals. The dosage of

the microorganism, which is delivered to the human body by the composition of the invention, can be regulated according to the administration pathway and subjects.

The composition of the invention can be administered to a subject at least once a day, everyday. Unit dosage indicates the unit separated physically to be appropriate for unit administration to a subject, either human or other mammals, and each unit contains a required amount of acceptable carrier and a required amount of the microorganism of the invention for the treatment effect. The unit dosage for oral administration of the composition of the invention is preferably 0.1-10 g and more preferably 0.5-5 g. The pharmaceutically effective dosage of the microorganism of the invention is 0.1-10 g/day. However, the dosage might vary according to the weight of a patient, the severity of obesity, and effective supplementary ingredients and microorganisms. The one day dosage can be divided into several sub-units so that they can be administered serially if necessary. Thus, the dosage of the composition of the invention cannot limit the spirit and scope of the invention in any way.

The regular administration of the composition of the invention results in the interruption of the absorption of saccharides inside the human body by releasing microorganisms to compete and form microflora, which interrupts the absorption, and further involves in the convert of monosaccharides such as carbohydrate into polysaccharides so as to inhibit the absorption thereof. In addition, dietary fiber produced by the microorganism provides preferable conditions for useful enterobacteria to grow with stimulating intestinal motility. Therefore, the composition of the invention can be effectively used for the prevention and treatment of obesity.

To maximize the weight reducing effect or obesity preventive effect of the pharmaceutical composition, any weight reducing agent known to those skilled in the art can be additionally included in the composition by a proper amount. The amount can be determined by those skilled in the art after multiple tests. The effective ingredient as an additive, the weight reducing agent, is preferably selected from the group consisting of conjugated linoleic acid, polydextrose, inulin, guar gum, arabic gum, L-carteine, grape seed extract, fructooligosaccharide, xylooligosaccharide, raffinose, gluconic acid, champignon, polyanthocyanidine, lactulose, lactitol, lactosucrose, Angelica gigas extract, Hovenia dulcis extract and tangerine peel extract, but not always limited thereto.

The present invention also provides a culture solution prepared by culturing *Lactobacillus gasseri* BNR17 (Accession No: KCTC 10902BP). The medium used to prepare the culture solution is not limited, and any medium that contains a medium for microorganism culture can be used. The culture solution of the invention can additionally contain any additive if necessary for a specific use. For example, to maximize the weight reducing effect, any weight reducing agent well known to those skilled in the art can be added to the culture solution and at this time the content of the agent can be determined by those skilled in the art after examining the effective dose range through repeated tests.

The present invention also provides a bacteriocin peptide produced by the lactic acid bacterium of the invention and a gene encoding the same. The present inventors named the bacteriocin peptide as "gassericin BNR17" which was confirmed to have the nucleotide sequence represented by SEQ. ID. NO: 5. The nucleotide sequence of the gassericin BNR17 was compared with that of the conventional antimicrobial peptide, gassericin T (NCBI Blast Search No.

AB029612, SEQ. ID. NO: 6), and as a result, the gassericin BNR17 had approximately 98% homology with the gassericin T.

The present invention further provides a recombinant vector containing the gassericin BNR17 gene.

The recombinant vector of the present invention can be prepared by inserting the gene having the nucleotide sequence represented by SEQ. ID. NO: 5 into a general expression vector for *E. coli*. The mother vector for the construction of the recombinant vector is not limited to a specific one, and almost every microorganism expression vector can be used but an *E. coli* expression vector is preferred.

The present invention also provides a transformant transformed with the recombinant vector.

The transformant of the invention can be easily generated by introducing the above recombinant vector into a random host cell. The host cell herein can be selected from the group consisting of eukaryotic or prokaryotic cells and multicellular animal originated cell lines, but not always limited thereto.

BRIEF DESCRIPTION OF THE DRAWINGS

The application of the preferred embodiments of the present invention is best understood with reference to the accompanying drawings, wherein:

FIG. 1 is a diagram showing the sequence comparison between *Lactobacillus gasseri* BNR17 of the invention (upper sequence in figure, SEQ. ID. NO: 1) and *Lactobacillus gasseri* KC26 (NCBI GENBANK Accession No: AF243156, lower sequence in figure, SEQ. ID. NO: 2) 16s rRNAs.

FIG. 2 is a microphotograph showing the enteric adherence of *Lactobacillus gasseri* BNR17 of the invention.

FIG. 3 is a set of photographs showing that *Lactobacillus gasseri* BNR17 of the invention has antimicrobial activity against various pathogenic bacteria.

FIG. 4 is a graph showing the glucose consumption and polysaccharide production according to the growth of *Lactobacillus gasseri* BNR17 of the invention.

■; cell growth, ◆; glucose concentration, ▲; EPS (polysaccharide) concentration

FIG. 5 is a graph showing the amount of feces of a rat taking *Lactobacillus gasseri* BNR17 of the invention.

FIG. 6 is a graph showing the EPS (polysaccharide) concentration in the feces of a rat taking *Lactobacillus gasseri* BNR17 of the invention.

FIG. 7 is a set of electrophoresis photographs showing the RAPD-PCR profiles of colonies isolated from other organs than the small intestine of a rat taking *Lactobacillus gasseri* BNR17 of the invention, in which primers represented by SEQ. ID. NO: 7 (A), NO: 8 (B) and NO: 9 (C) were used.

Lane 1; *Lb. gasseri* BNR17, Lanes 2-5; colonies isolated from other organs than the small intestine of a rat taking *Lb. gasseri* BNR17,

M; DNA size marker.

EXAMPLES

Practical and presently preferred embodiments of the present invention are illustrative as shown in the following Examples.

However, it will be appreciated that those skilled in the art, on consideration of this disclosure, may make modifications and improvements within the spirit and scope of the present invention.

Example 1

Lactic Acid Bacterium Isolation from Human
Mother's Milk

Human mother's milk was taken from a woman delivered of a baby not more than two weeks ago. Then, the mother's milk was diluted with PBS and the undiluted milk and diluted milk were distributed on a lactobacillus selection medium respectively. The medium was cultured at 37° C. for 2-3 days and the colonies generated therein were sorted by morphology and color. The isolated colonies were Gram-stained and observed under a microscope to select those colonies that were Gram-positive and had rod-shaped structure. The selected colonies were cultured in MRS liquid medium (pH 6.8) at 37° C. for 24 hours. Colonies in the culture solution under the pH lower than 4.5 were selected. The colonies were cultured in MRS medium (pH 2.0) for 2

ing. As a result, the strain was confirmed to belong *Lactobacillus gasseri* species (SEQ. ID. NO: 1, FIG. 1) and named as "Lactobacillus gasseri BNR17".

Example 2

Sugar Utilization of the Isolated Lactic Acid
Bacterium

Sugar utilization of *Lactobacillus gasseri* BNR17 of the invention isolated above was investigated by comparing with other standard strains using API50CHL kit (Biomérieux, France) and the results are shown in Table 1. In Table 1, 5314 indicates *Lactobacillus gasseri* CECT5714; 5315 indicates *Lactobacillus gasseri* CECT5715; 11413 indicates *Lactobacillus gasseri* LMG11413; 18194 indicates *Lactobacillus gasseri* LMG18194; 4479 indicates *Lactobacillus gasseri* CECT4479; 18176 indicates *Lactobacillus gasseri* LMG18176; and 13047 indicates *Lactobacillus gasseri* LMG13047.

TABLE 1

| | BNR17 | 5714 | 5715 | 11413 | 18194 | 4479 | 18176 | 13047 |
|----------------------|-------|------|------|-------|-------|------|-------|-------|
| Glycerol | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Erythritol | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D-Arabinose | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 |
| L-Arabinose | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 |
| Ribose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D-Xylose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| L-Xylose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Adonitol | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| β-Methyl-xyloside | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Galactose | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| D-Glucose | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| D-Fructose | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| D-mannose | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| L-Sorbose | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 |
| Rhamnose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dulcitol | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
| Inositol | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mannitol | 0 | 0 | 3 | 5 | 0 | 0 | 0 | 0 |
| Sorbitol | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| α-Methyl-D-mannoside | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| α-Methyl-D-glucoside | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| N-Acetylglu-cosamine | 5 | 4 | 5 | 5 | 5 | 5 | 5 | 5 |
| Amygdalin | 5 | 5 | 5 | 0 | 0 | 5 | 5 | 0 |
| Arbutine | 5 | 5 | 5 | 1 | 1 | 5 | 5 | 4 |
| Esculine | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Salicine | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 3 |
| Cellobiose | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Maltose | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Lactose | 5 | 0 | 4 | 5 | 5 | 5 | 5 | 0 |
| Melibiose | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Saccharose | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Trehalose | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Inuline | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Melezilose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D-Raffinose | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 |
| Armidon | 5 | 3 | 5 | 1 | 1 | 5 | 3 | 3 |
| Glycogene | 0 | 0 | 0 | 4 | 4 | 0 | 0 | 0 |
| Xylitol | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| b-Gentobiose | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| D-Turanose | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D-Lycose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D-Tagatose | 5 | 5 | 5 | 3 | 3 | 5 | 5 | 5 |
| D-Fucose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| L-Fucose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D-Arabinol | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

hours, followed by further culture in MRS medium supplemented with 0.3% oxgall for 9 hours. The survived lactobacillus strain that exhibited acid resistance and bile acid resistance was isolated and identified by 16S rRNA sequenc-

As shown in Table 1, compared with other lactobacillus strains, the *Lactobacillus gasseri* BNR17 of the invention was distinguishable in sugar utilization from others (shown in thick Italics).

11

Example 3

Enzyme Activity of the Isolated Lactic Acid Bacterium

The enzyme activity of the *Lactobacillus gasseri* BNR17 isolated in Example 1 was compared with those of other standard strains using APIZYM kit (Biomérieux, France) and the results are shown in Table 2. In Table 2, 13134 indicates *Lactobacillus gasseri* LMG13134.

TABLE 2

| | BNR17 | 11413 | 13047 | 13134 | 18176 | 18194 | 4479 | 5714 | 5715 |
|--|-------|-------|-------|-------|-------|-------|------|------|------|
| Control | - | - | - | - | - | - | - | - | - |
| Alkaline phosphates | - | - | - | - | - | - | - | - | - |
| Esterase (C4) | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Esterase lipase (C8) | - | - | - | 1 | - | - | - | - | - |
| Lipase (C4) | - | - | - | - | - | - | - | - | - |
| Leucine | + | + | + | + | + | + | + | + | + |
| arylamidase | | | | | | | | | |
| <i>Valine</i> | 1 | 1 | 1 | 3 | 2 | - | - | - | 1 |
| <i>arylamidase</i> | | | | | | | | | |
| <i>Cystine</i> | 1 | 1 | 1 | 4 | 2 | 3 | 4 | 1 | 1 |
| <i>arylamidase</i> | | | | | | | | | |
| Trypsin | - | - | - | - | - | - | - | - | - |
| α -chymotrypsin | - | - | 1 | - | - | - | - | - | - |
| <i>Acid phosphatase</i> | + | 1 | 2 | + | - | 1 | 2 | 1 | 1 |
| <i>Naphthol-As-BI-phosphohydrolase</i> | + | 1 | + | + | + | - | + | + | + |
| <i>α-galactosidase</i> | + | + | - | - | + | - | + | + | + |
| <i>β-galactosidase</i> | + | 4 | 1 | 3 | - | - | - | - | - |
| <i>β-glucuronidase</i> | - | + | + | - | - | - | - | - | - |
| <i>α-glucosidase</i> | 1 | 1 | + | - | 1 | 2 | 1 | - | 1 |
| <i>β-glucosidase</i> | 3 | + | - | 3 | + | - | 3 | 4 | + |
| <i>N-acetyl-β-glucosaminidase</i> | 1 | + | 1 | - | + | - | - | - | 1 |
| α -mannosidase | - | - | - | - | - | - | - | - | - |
| α -fucosidase | - | - | - | - | - | - | - | - | - |

As shown in Table 2, the *Lactobacillus gasseri* BNR17 of the invention was distinguishable in enzyme activity from other strains (shown in thick Italics).

Example 4

Acid Resistance and Bile Acid Resistance

To investigate acid resistance and bile acid resistance of the strain of the invention, *Lactobacillus gasseri* BNR17 was inoculated in 4 ml of MRS liquid medium and cultured at 37° C. for 18-20 hours. Some of the culture solution was reinoculated in another MRS medium with regulated pH of 2.0 at the concentration of 10⁷ CFU/ml and cultured at 37° C. for 2 hours. The number of live cells was counted using MRS agar plate. The culture solution tested for acid resistance was used again for centrifugation. The cells were recovered and inoculated in MRS liquid medium (pH 6.8) supplemented with 0.3% oxgall, followed by culture at 37° C. for 9 hours. The number of live cells was also counted using MRS agar plate. The results are shown in Table 3.

TABLE 3

| | Before treatment | Treatment at pH 2.0 | 0.3% oxgall treatment |
|-------|-----------------------|-----------------------|-----------------------|
| BNR17 | 3.1 × 10 ⁷ | 2.1 × 10 ⁷ | 1.5 × 10 ⁷ |

12

As a result, even after the treatment with strong acid (pH 2.0), the *Lactobacillus gasseri* BNR17 exhibited high survival rate, and so did in the medium supplemented with 0.3% oxgall.

Example 5

Enteric Adherence

The strain of the invention was inoculated on the plate on which a human intestinal epithelial cell line CaCo-2 was

cultured in PRMI1640 (Gibco) at the concentration of 10⁷ CFU/ml. The strain was cultured at 37° C. for one hour, followed by washing three times with PBS to eliminate non-adhered cells. The sample was fixed with methanol and then stained with crystal violet, followed by observation under a microscope. As a result, the *Lactobacillus gasseri* BNR17 of the invention was confirmed to be very well adhered on CaCo-2 cells (FIG. 2).

Example 6

Antimicrobial Activity Against Pathogenic Bacteria

E. coli, *S. aureus*, *S. typhimurium*, *B. cereus*, *L. monocytogenes* and *P. mirabilis* were cultured at 37° C. for 18 hours in BHI liquid medium (Difco) and then inoculated in 6 of 5 ml BHI agar media (agar content: 0.7%) respectively at the concentration of 10⁵ CFU/ml. These media were overlapped on 6 plates with BHI agar media (agar content: 1.5%) fixed thereon. After hardening those 6 plate media, a well of 4 mm in diameter was made in each medium, in which 40 μ l of the supernatant (2 \times) of lactic acid bacterium culture solution cultured at 37° C. for 24 was added, followed by culture at 37° C. for 5 hours.

As a result, a clear growth inhibition ring was observed around the well, suggesting that the strain of the invention has antimicrobial activity against various pathogenic bacteria (Table 4 and FIG. 3).

13

TABLE 4

| Pathogenic bacteria | Diameter of growth inhibition ring (mm) |
|---------------------------|---|
| E. coli KCTC1039 | 16 |
| B. cereus KCTC1526 | 16 |
| L. monocytogenes KCTC3710 | 12 |
| P. mirabilis KCTC2510 | 14 |
| S. aureus KCTC1928 | 6 |
| S. typhimurium KCTC2421 | 18 |

Example 7

Antibiotic Resistance

Lactobacillus gasseri BNR17 culture solution was smeared on MRS agar plate by using a swab, on which a disc containing erythromycin, penicillin, gentamycin, kanamycin, streptomycin, bacitracin, chloramphenicol, vancomycin, tetracycline, ampicillin, cefoxitin, rifampin, neomycin, nalidixic acid, ciprofloxacin, polymyxin B or trimethoprim was placed, followed by culture at 37° C. for 24 hours.

As a result, Lactobacillus gasseri BNR17 of the invention was confirmed to have resistance against gentamycin, streptomycin and trimethoprim.

Example 8

Detection of the Antimicrobial Peptide Gene

Bacteriocin gene was investigated by PCR performed by using the Lactobacillus gasseri BNR17 genomic DNA as a template and primers represented by SEQ. ID. NO: 3 and NO: 4 which were specific to the nucleotide sequence of a gene of bacteriocin known as an antimicrobial peptide produced by Lactobacillus gasseri species.

As a result, the PCR product corresponding to gassericin was confirmed and represented by SEQ. ID. NO: 5. The nucleotide sequence was compared with that of gassericin T (NCBI Blast Search No. AB029612) represented by SEQ. ID. NO: 6 and confirmed to have approximately 98% homology.

Example 9

 β -glucuronidase Activity

β -glucuronidase produced by enterobacteria has been known as one of oncogenic enzymes and thus the strain that has this enzyme activity is considered as a harmful strain. To investigate whether the Lactobacillus gasseri BNR17 of the invention has β -glucuronidase activity or not, the enzyme activity of Lactobacillus gasseri BNR17 was tested using API ZYM kit (Biomerieux, France).

As a result, the strain of the invention was confirmed not to have β -glucuronidase activity, suggesting that the strain was safe (Table 5).

TABLE 5

| Enzyme | Activity |
|-------------------------|----------|
| α -galactosidase | Positive |
| β -galactosidase | Positive |
| β -glucuronidase | Negative |
| α -glucosidase | Negative |
| β -glucosidase | Positive |

14

Example 10

Glucose Consumption and Polysaccharide Production

Lactobacillus gasseri BNR17 was inoculated in MRS medium (Difco) prepared by adding 2% glucose (w/v) at the concentration of 10^6 cfu/ml and cultured for 96 hours, during which the cell number was measured stepwise and at the same time glucose consumption and extracellular polysaccharide (EPS) production were measured as well.

As a result, the highest level of Lactobacillus gasseri BNR17 was observed on the 12th hour of culture and since then the level had been decreased. Glucose concentration was rapidly reduced after 7 hours of culture and no changes of glucose concentration were detected after 36 hours, suggesting that most of glucose was consumed within 36 hours from the culture started. EPS production was maximized on the 24th hour (the highest level: 520 mg/k) and was slightly reduced on the 36th hour but increased again thereafter. It was presumed to be attributed to autolysis of the cells causing various polysaccharides in the cells to be released into the culture solution (FIG. 4).

Example 11

Decomposition of the Polysaccharide Produced by Lactobacillus Gasseri BNR17 by a Digestive Enzyme

100 mg of each α -amylase (Sigma) and pancreatin (Sigma) was dissolved in 0.05 M phosphate buffer (pH 7.0). 50 μ l of the above enzyme solution and 150 μ l of 0.05 M phosphate buffer (pH 7.0) were added to 200 μ l of polysaccharide (EPS) solution extracted from the supernatant of Lactobacillus gasseri BNR17 culture solution, followed by reaction at 37° C. for one hour. The reaction mixture was heated at 100° C. for 15 minutes to inactivate enzymes therein, followed by cooling at room temperature. Glucose concentration was measured with a glucose kit (Sigma).

As a result, glucose was not detected in the polysaccharide solution before the treatment of each digestive enzyme, while 3.70 mg/l and 19.1 mg/l of glucose were respectively detected after the treatment of pancreatin and α -amylase. This result indicates that the polysaccharide produced by Lactobacillus gasseri BNR17 was hardly decomposed by a digestive enzyme.

Example 12

Weight Gaining Inhibitory Effect of Lactobacillus Gasseri BNR17

8 week old male SD rats were grouped into two. One group was orally administered with PBS only (pH 7.4) and the other group was orally administered with PBS suspended with 10^9 CFU/ml of Lactobacillus gasseri BNR17, everyday for 8 weeks. Changes of weights, food intakes, and blood chemical values such as cholesterol level were measured once a week. The amounts of feces and EPS in feces were also measured to investigate the relation of weight gaining inhibitory effect of Lactobacillus gasseri BNR17 and polysaccharide production capacity thereof. 8 weeks later, all the test animals were sacrificed and dissected to extract the liver, kidney, spleen, MLN (mesenteric lymph node), which were measured their weights. Some of each organ extracted was homogenized and smeared on LBS agar, a lactobacillus

15

selection medium, which was then cultured and RAPD (random amplified polymorphic DNA)-PCR profiles of the generated colonies were investigated. The result was compared with the RAPD-PCR profile of *Lactobacillus gasseri* BNR17 to investigate whether the strain was transferred to other organs.

As a result, approximately 179.1% weight increase was observed for 8 weeks in the control group orally administered with PBS only, while approximately 171.6% weight increase was observed in the experimental group orally administered with *Lactobacillus gasseri* BNR17 (Table 6). The experimental group also exhibited lower rates of one-day weight increase and food efficiency ratio than the control.

TABLE 6

| Group | Weight (g) | | Weight gaining (g/day) | Food efficiency ratio** |
|---------|-----------------|-----------------|------------------------|-------------------------|
| | Initial weight | Final weight* | | |
| Control | 221.20 ± 3.759 | 393.73 ± 4.860 | 3.081 | 0.131 ± 0.078 |
| BNR17 | 223.66 ± 10.077 | 380.85 ± 21.517 | 2.807 | 0.115 ± 0.067 |

In Table 6, food efficiency ratio (FER) indicates weight gaining (g day)/food intake (g day). *P<0.05, **P<0.05.

The results of measuring the amounts of feces and EPS in feces of both the control and the experimental groups are shown in FIG. 5 and FIG. 6. The amounts of feces were not much different between the control and the experimental groups, but the ESP amount was significantly increased in the experimental group administered with *Lactobacillus gasseri* BNR17. This result indicates that *Lactobacillus gasseri* BNR17 converts sugar components taken inside body into indigestible polysaccharides so as to release the polysaccharides out of the body, resulting in the decrease of in vivo absorption rate and inhibition of weight gaining.

To examine safety of the strain for human administration, blood chemical values and organ weights were measured. Each levels and values were similar in the control and the experimental groups, suggesting that the strain did not cause side effects (Table 7 and Table 8).

TABLE 7

| Group | Cholesterol (mg/dL) | Glucose (mg/dL) | HDL (mg/dL) | LDL (mg/dL) | Total protein (g/dL) | Triglyceride (mg/dL) |
|---------|---------------------|-----------------|-------------|-------------|----------------------|----------------------|
| Control | 99.7 ± 11.7 | 88.9 ± 12.1 | 38.5 ± 3.5 | 21.5 ± 1.6 | 8.6 ± 0.3 | 115.9 ± 11.0 |
| BNR17 | 96.3 ± 6.3 | 79.2 ± 4.1 | 40.8 ± 1.8 | 20.8 ± 3.1 | 9.0 ± 0.3 | 132.6 ± 5.5 |

TABLE 8

| Group | Liver | Kidney | Spleen |
|---------|---------------|---------------|---------------|
| Control | 0.029 ± 0.001 | 0.007 ± 0.000 | 0.002 ± 0.000 |
| BNR17 | 0.027 ± 0.003 | 0.007 ± 0.001 | 0.002 ± 0.000 |

In Table 8, each number indicates organ weight (g)/rat weight (g).

To investigate whether the strain was transferred to other organs, RAPD-PCR profiles of colonies of each organ tissue cultured on LBS agar plate were investigated by using primers p1, p2 and OPL5 respectively represented by SEQ. ID. NO: 7-NO: 9. PCR using the primers p1 and p2 was performed as follows; 94° C. (2 minutes), 36° C. (5 min-

16

utes), 72° C. (5 minutes)—4 cycles/94° C. (1 minute), 36° C. (1 minute), 72° C. (2 minutes)—36 cycles. PCR using the primer OPL5 was performed as follows; 94° C. (2 minutes)—1 cycle/94° C. (40 seconds), 45° C. (1 minute), 72° C. (1 minute)—2 cycles/94° C. (40 seconds), 52° C. (1 minute), 72° C. (3 minutes)—30 cycles/70° C. (5 minutes)—1 cycle.

As a result, no colonies exhibited similar profiles to BNR17 (FIG. 7). Thus, BNR17 was confirmed to be safe strain which is not transferred to other organs except the small intestine when it is taken.

Manufacturing Example 1

Preparation of Fermented Milk

Raw milk in which milk solid non fat content was regulated by 8-20% using powdered skim milk was sterilized at 72-75° C. for 15 seconds. The sterilized raw milk was cooled down to the proper temperature, to which *Lactobacillus gasseri* BNR17 of the invention was inoculated at the concentration of 10⁶ cfu/ml, followed by culture until pH reached 4-5. Upon completion of the culture, the culture solution was cooled down. In the meantime, 0.1-50 weight % of fruit juice concentrate, 0.1-20 weight % of dietary fiber, 0.5-30 weight % of glucose, 0.1-15 weight % of oligosaccharide, 0.01-10 weight % of calcium and 0.001-5 weight % of vitamin were all dissolved to prepare syrup. The syrup was sterilized, cooled down, and mixed with the above culture solution, followed by stirring for homogenization. The resultant mixture was packed, resulting in the preparation of fermented milk. Flavor, physical property, and taste of the fermented milk product were tested, and the results were satisfactory.

Manufacturing Example 2

Preparation of Lactic Acid Bacteria Powder

Lactobacillus gasseri BNR17 of the invention was inoculated into MRS liquid medium at the concentration of 10⁶

cfu/ml, followed by pH-control fermentation at 37° C. for 18-24 hours. pH-control was performed by using 30 volume % NaOH as a neutralizing agent to pH 5.7±0.2. Upon completion of the culture, centrifugation was performed at 4° C. with 10,000×g to recover cells. A protectant supplemented with 5 weight % of skim milk, 2.5 weight % of whey, and 5 weight % of sucrose (for the total weight of the composition) was prepared. Equal amounts of the recovered cells and the protectant were mixed, followed by pulverization by using a freeze dryer. The produced *Lactobacillus gasseri* BNR17 dried powder contained over 1×10¹¹ cfu/g live cells. The protectant can additionally include 10 weight % of trehalose, 10 weight % of maltodextrine and 7.5 weight % of lactose.

Manufacturing Example 3

Preparation of Lactic Acid Bacteria Products

Lactic acid bacteria products such as lactic acid bacteria foods and digestives were prepared from the lactic acid bacteria powder produced in Manufacturing Example 2. 10 weight % of oligosaccharide, 20 weight % of anhydrous glucose, 5 weight % of crystalline fructose, 2 weight % of vitamin C, 5 weight % of fruit powder flavor, 5 weight % of aloe, 15 weight % of dietary fiber, and 18 weight % of Psyllium Husk were added to 20 weight % of Lactobacillus gasseri BNR17 dried powder, and the mixture was packed in sticks or bottles. The live cells in the lactic acid bacteria product prepared thereby were more than 5×10^8 cfu/g.

Manufacturing Example 4

Preparation of a Composition for Feed Additive

A composition for feed additive containing Lactobacillus gasseri BNR17 was prepared by the following compositions shown in Table 9.

TABLE 9

| Component ratio of the composition for feed additive (weight %) | | | | | |
|---|-----------------------------|--------------------|------------------------------|------------|--------|
| | Lactobacillus gasseri BNR17 | Enzyme preparation | Nonpathogenic micro-organism | Amino acid | Others |
| Manufacturing Example <4-1> | 100 | — | — | — | — |
| Manufacturing Example <4-2> | 90 | 10 | — | — | — |

TABLE 9-continued

| Component ratio of the composition for feed additive (weight %) | | | | | |
|---|-----------------------------|--------------------|------------------------------|------------|--------|
| | Lactobacillus gasseri BNR17 | Enzyme preparation | Nonpathogenic micro-organism | Amino acid | Others |
| Manufacturing Example <4-3> | 80 | 10 | 10 | — | — |
| Manufacturing Example <4-4> | 70 | 10 | 10 | 10 | — |
| Manufacturing Example <4-5> | 60 | 15 | 15 | 8 | 2 |
| Manufacturing Example <4-6> | 50 | 20 | 15 | 8 | 2 |

The enzyme preparation used herein was a mixture of phytase, cellulase, xylase, maltase and invertase, and the non-pathogenic microorganism was *Aspergillus oryzae*.

INDUSTRIAL APPLICABILITY

As explained hereinbefore, the Lactobacillus gasseri BNR17 of the invention has wide growth temperature and pH ranges allowed. And, the strain of the invention not only has excellent acid resistance, bile acid resistance and enteric adsorption capacity but also strong antimicrobial activity against pathogenic microorganisms, in addition to weight gaining inhibitory effect. Therefore, the strain of the invention can be effectively used for the production of fermented milk and other fermented products and be very useful as an additive for animal feed as well.

SEQUENCE LISTING

Sequence listing is attached herewith.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 9

<210> SEQ ID NO 1

<211> LENGTH: 840

<212> TYPE: DNA

<213> ORGANISM: Lactobacillus gasseri BNR17

<220> FEATURE:

<221> NAME/KEY: misc_feature

<222> LOCATION: (181)..(181)

<223> OTHER INFORMATION: n i s a , c , g , o r t

<400> SEQUENCE: 1

```

gctgactcct ataaaggcta tcccaccggc ttgggtggtt acagactctc atgggtgtgac      60
ggcggtgtg tacaaggccc gggaacgtat tcaccggggc gtgctgatcc gcgattacta      120
gcgattocag ctctcgttag gcgagttgca gcctacagtc cgaactgaga acggctttca      180
nagatccgct tgccttcgca ggttcgcttc tcgttgtaac gtccattgta gcacgtgtgt      240
agcccaggtc ataaggggca tgatgacttg acgtcatccc caccttcctc cggtttgtca      300
ccggcagttc cattagagtg cccaacttaa tgatggcaac taatgacaag gggtgcgctc      360
gttgcgggac ttaacccaac atctcacgac acgagctgac gacagccatg caccacctgt      420
ctcagcgtcc ccgaagggaa ctctaatct cttaggtttg cactggatgt caagacctgg      480
taaggttctt cgcgttgctt cgaattaaac cacatgctcc accgcttgtg cgggcccccg      540
tcaattcctt tgagtttcaa ccttgcggtc gtactcccca ggccggagtgc ttaatgcgtt      600
agctgcagca ctgagaggcg gaaacctccc aaccttagc actcatcgtt tacggcatgg      660

```


-continued

```

actaccaggg tatctaacc tgttcgctac ccatgctttc gagcctcagc gtcagttgca 720
gaccagagag cgccttcgc cactgggtgtt cttccatata tctacgcatt ccaccgctac 780
acatggagtt ccactctcct cttctgcact caagttcaac agtttctgat gcaattctcc 840

```

```

<210> SEQ ID NO 2
<211> LENGTH: 840
<212> TYPE: DNA
<213> ORGANISM: Lactobacillus gasseri KC26

```

```

<400> SEQUENCE: 2

```

```

gctgactcct ataaaggta tcccaccggc tttgggtgtt acagactctc atgggtgtgac 60
gggcggtgtg tacaaggccc ggaacgtat tcaccgcggc gtgctgatcc gcgattacta 120
gcgattccag cttcgtgtag gcgagttgca gcctacagtc cgaactgaga acggctttca 180
gagatccgct tgccttcgca ggttcgcttc tcgttgatcc gtccattgta gcacgtgtgt 240
agcccaggtc ataaggggca tgatgacttg acgtcatccc caccttcctc cggtttgta 300
ccggcagttc cattagagtg cccaacttaa tgatggcaac taatgacaag ggttgcgctc 360
gttgccggac ttaaccaac atctcagac acgagctgac gacagccatg caccacctgt 420
ctcagcgccc ccgaaggaa ctctaactc cttaggtttg cactggatgt caagacctgg 480
taaggttcct cgcgttgctt cgaattaaac cacatgctcc accgcttggt cgggcccccg 540
tcaattcctt tgagtttcaa ccttgccggtc gtactcccca ggccgagtg ttaatgcgtt 600
agctgcagca ctgagaggcg gaaacctccc aacacttagc actcatcgtt tacggcatgg 660
actaccaggg tatctaacc tgttcgctac ccatgctttc gagcctcagc gtcagttgca 720
gaccagagag cgccttcgc cactgggtgtt cttccatata tctacgcatt ccaccgctac 780
acatggagtt ccactctcct cttctgcact caagttcaac agtttctgat gcaattctcc 840

```

```

<210> SEQ ID NO 3
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gaT-950 forward primer, specific to
Lactobacillus gasseri

```

```

<400> SEQUENCE: 3

```

```

ggagtaggtg gagcgacagt 20

```

```

<210> SEQ ID NO 4
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gaT-1075 reverse primer, specific to
Lactobacillus gasseri

```

```

<400> SEQUENCE: 4

```

```

tccaccagta gctgccgta 20

```

```

<210> SEQ ID NO 5
<211> LENGTH: 110
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gassericin BNR17 gene originated from
Lactobacillus gasseri BNR17

```

```

<400> SEQUENCE: 5

```


-continued

```

tgccgttacg ccagcccatg ctattggaac atagtgtgct ccaacagagc cacaagcagg      60
accgcaaact gcatttcaa gagcccgtcc agcgactgtc gctccaccta      110

```

```

<210> SEQ ID NO 6
<211> LENGTH: 110
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gassericin T gene originated from Lactobacillus
gasseri and disclosed in NCBI Blast Search No. AB029612

<400> SEQUENCE: 6

```

```

tgccgttacg ccagcccatg ctattggaac atagtgtgct ccaacaaagc cacaagcagg      60
accgcaaact gcatttcaa gagcccaccc agcgactgtc gctccaccta      110

```

```

<210> SEQ ID NO 7
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer p1, random sequence according to
RAPD-PCR technique

<400> SEQUENCE: 7

```

```

agcagcgtgg      10

```

```

<210> SEQ ID NO 8
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer p2, random sequence according to
RAPD-PCR technique

<400> SEQUENCE: 8

```

```

ggcatgacct      10

```

```

<210> SEQ ID NO 9
<211> LENGTH: 10
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: primer OPL5, random sequence according to
RAPD-PCR technique

<400> SEQUENCE: 9

```

```

acgcaggcac      10

```

What is claimed is:

[1.] A *Lactobacillus gasseri* BNR17 strain of a biologically pure culture deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.]

[2.] The *Lactobacillus gasseri* BNR17 strain according to claim 1, wherein the strain contains 16S rRNA sequence represented by SEQ ID NO: 1.]

[3.] A composition containing an effective dose of the *Lactobacillus gasseri* BNR17 of claim 1.]

[4.] The composition according to claim 3, wherein the composition is selected from the group consisting of food, food additive, animal feed and animal feed additive.]

[5.] The composition according to claim 4, wherein the animal feed additive contains at least one selected from the group consisting of other non-pathogenic microorganisms, enzymes and a mixture thereof.]

[6.] A pharmaceutical composition comprising [an effective dose of the] *Lactobacillus gasseri* BNR17 [of claim 1] strain in an enteric coating, wherein the *L. gasseri* BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

[7.] A culture solution of the *Lactobacillus gasseri* BNR17 of claim 1.]

[8.] A method for inhibiting weight gain comprising administering to a subject an [effective dose] amount of [the] *Lactobacillus gasseri* BNR17 [of claim 1] strain, wherein the *L. gasseri* BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

[9.] A fermented food product comprising *Lactobacillus gasseri* BNR17 strain, wherein the *L. gasseri* BNR17 strain

is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

10. The fermented food product according to claim 9, wherein the fermented food product is a dairy product.

11. A fermented food product having a bacterial component, the bacterial component consisting essentially of *Lactobacillus gasseri* BNR17 strain, wherein the *L. gasseri* BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

12. The fermented food product according to claim 11, wherein the fermented food product is a dairy product.

13. A dry powder comprising live *Lactobacillus gasseri* cells and a protectant that inhibits death of the *Lactobacillus gasseri* cells during a drying step, wherein the live *Lactobacillus gasseri* cells are of the *Lactobacillus gasseri* BNR17 strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP, and wherein the protectant comprises 5 weight % powdered skim milk, 2.5 weight % of whey, and 5 weight % of sucrose of the total weight of the dry powder.

14. A food product comprising the dry powder of claim 13.

15. A feed product for a non-human animal comprising an animal feedstock and *Lactobacillus gasseri* BNR17 strain, wherein the *L. gasseri* BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

16. A tablet or capsule comprising the dry powder of claim 13.

17. The tablet or capsule according to claim 16, wherein the tablet or capsule further comprises a pharmaceutically acceptable carrier or excipient.

18. A formulation comprising *Lactobacillus gasseri* BNR17 strain, a diluent, a high-fiber additive, an encapsulant, and a lipid, wherein the *L. gasseri* BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

19. A method for treating obesity or inhibiting weight gain in an adult human, the method comprising administering to the human a composition comprising *Lactobacillus gasseri* BNR17 strain, wherein the *L. gasseri* BNR17 strain is the strain deposited at Korean Collection for Type Culture of

Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

20. A method for inhibiting saccharide absorption in an adult mammal, the method comprising administering to the mammal a composition comprising *Lactobacillus gasseri* BNR17 strain, wherein the *L. gasseri* BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

21. A method for inhibiting weight gain or treating obesity in a non-human mammal, comprising administering to the mammal a composition comprising *Lactobacillus gasseri* BNR17 strain, wherein the *L. gasseri* BNR17 strain is the strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

22. The method according to claim 21, comprising administering 0.1-10 g/day of the *Lactobacillus gasseri* BNR17.

23. The pharmaceutical composition according to claim 6, wherein the *L. gasseri* BNR17 strain inhibits weight gain.

24. The dry powder of claim 13, wherein the protectant further comprises 10 weight % trehalose, 10 weight % maltodextrin, and 7.5 weight % lactose.

25. The feed product of claim 15, wherein the feed product further comprises one or more selected from the group consisting of a diluent, a high-fiber additive, an encapsulant, a lipid, an enzyme and a non-pathogenic microorganism.

26. The feed product of claim 25, wherein the enzyme is selected from the group consisting of phytase, cellulose, xylase, maltase, invertase, and a combination thereof.

27. The feed product of claim 25, wherein the non-pathogenic organism is *Aspergillus oryzae*.

28. A method of producing a food product, comprising mixing a dry powder comprising live *Lactobacillus gasseri* cells and a protectant that inhibits death of the *Lactobacillus gasseri* cells during a drying step, with a food, wherein the live *Lactobacillus gasseri* cells are of the *Lactobacillus gasseri* BNR17 strain deposited at Korean Collection for Type Culture of Korea Research Institute of Biotechnology and Bioscience under the Accession number of KCTC 10902BP.

29. The method of claim 28, wherein the protectant comprises 5 weight % powdered skim milk, 2.5 weight % of whey, and 5 weight % of sucrose of the total weight of the dry powder.

* * * * *

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : RE46,912 E
APPLICATION NO. : 14/537565
DATED : June 26, 2018
INVENTOR(S) : Kang et al.

Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Specification

At Column 1, under the heading "CROSS REFERENCE TO RELATED APPLICATIONS," replace Line 17 (approx.) and the portion of Line 18 (approx.) that includes "8,309,076, issued on Nov. 13, 2012," with the following:

--NOTICE: More than one reissue application has been filed for the reissue of U.S. Patent No. 8,309,076 B2. The reissue applications are U.S. Reissue Patent Application Serial No. 15/978,986, filed on May 14, 2018, which is a continuation reissue application of U.S. Reissue Patent Application Serial No. 14/537,565 (the present application), filed on November 10, 2014, now U.S. Reissue Patent No. RE46,912 E, issued June 26, 2018, which is a reissue application of U.S. Patent Application Serial No. 12/376,368, filed on March 17, 2010, now U.S. Patent No. 8,309,076 B2, issued November 13, 2012,--

Signed and Sealed this
Twenty-third Day of March, 2021



Drew Hirshfeld
Performing the Functions and Duties of the
Under Secretary of Commerce for Intellectual Property and
Director of the United States Patent and Trademark Office